MARKET

MNOV

MNOV

MediciNova Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.34
0.00
0.00%
Closed 16:00 05/29 EDT
OPEN
5.28
PREV CLOSE
5.34
HIGH
5.36
LOW
5.13
VOLUME
64.67K
TURNOVER
--
52 WEEK HIGH
11.12
52 WEEK LOW
2.790
MARKET CAP
235.32M
P/E (TTM)
-21.1821
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNOV stock price target is 17.67 with a high estimate of 24.00 and a low estimate of 11.00.

EPS

MNOV News

More
IPO Update: Pliant Therapeutics Readies U.S. IPO
Seeking Alpha - Article · 4d ago
MNOV: Multiple ‘Shots on Goal’ Provide Substantial Potential Upside…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Multiple Reasons for MediciNova to Move Higher MediciNova, Inc. (NASDAQ:MNOV) is a biopharmaceutical company focused on developing small molecule therapies for treating a range
Zacks Small Cap Research · 05/01 15:30
Have Insiders Been Buying MediciNova, Inc. (NASDAQ:MNOV) Shares This Year?
Simply Wall St. · 04/27 15:20
MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
GlobeNewswire · 04/21 00:00
AR, CORR, SPCE and NBEV among midday movers
Seeking Alpha - Article · 04/14 16:40
MNOV: MN-166 Trial in ARDS to Initiate at Yale University
Zacks Small Cap Research · 04/14 14:20
RIG, OKE among premarket gainers
Seeking Alpha - Article · 04/13 13:21
PSTI, TUP, AKER and CAPR among midday movers
Seeking Alpha - Article · 04/09 16:44

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About MNOV

Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
More

Webull offers kinds of MediciNova, Inc. stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.